Julie McHugh
Known title: DirectorCIK: 0001487179
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Lantheus Holdings receives Mizuho downgrade to neutral. Lantheus Holdings was downgraded to neutral by Mizuho, which also cut its price target to $109. The downgrade appeared alongside other recent analyst cuts highlighted in a Benzinga roundup of top downgrades. The new target sits near the current analyst consensus of $107.22 and close to the stock’s 52‑week high, while the RSI is around the midpoint.
Transaction History
| IRWD | ▲ Buy | Grant | 63,481 | $0 | 6/16/2026 | View on chart |
| IRWD | ▼ Sell | Open Market | 21,571 | $80K | 6/16/2026 | View on chart |
| LNTH | ▲ Buy | Grant | 4,137 | $0 | 5/14/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 45,000 | $0 | 6/10/2025 | View on chart |
| LNTH | ▼ Sell | Open Market | 5,192 | $424K | 6/9/2025 | View on chart |
| LNTH | ▲ Buy | Grant | 2,537 | $0 | 5/14/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 24,311 | $0 | 6/18/2024 | View on chart |
| IRWD | ▼ Sell | Open Market | 22,766 | $143K | 6/10/2024 | View on chart |
| LNTH | ▼ Sell | Open Market | 2,500 | $196K | 5/28/2024 | View on chart |
| LNTH | ▲ Buy | Grant | 2,635 | $0 | 5/9/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 22,350 | $0 | 6/20/2023 | View on chart |
| LNTH | ▲ Buy | Grant | 2,012 | $0 | 5/11/2023 | View on chart |
| LNTH | ▼ Sell | Open Market | 4,300 | $338K | 9/6/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 21,571 | $0 | 6/1/2022 | View on chart |
| LNTH | ▼ Sell | Open Market | 2,980 | $172K | 5/11/2022 | View on chart |
| LNTH | ▲ Buy | Grant | 2,180 | $0 | 5/6/2022 | View on chart |
| IRWD | ▼ Sell | Open Market | 20,000 | $233K | 3/14/2022 | View on chart |
| IRWD | ▼ Sell | Open Market | 10,000 | $110K | 12/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO
Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.